Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $30 to $26.
Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $30 to $26.